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Abstract
Percutaneous coronary intervention is currently the most common revas-
cularization procedure for coronary artery stenosis. Bare metal stents 
effectively reduce the rates of acute closure and restenosis more suc-
cessfully than balloon angioplasty. However, the rates of restenosis remain 
high. Local delivery of drugs using drug-eluting stents to inhibit neointimal 
pro liferation was proven to be an effective method to reduce in-stent res-
tenosis and hence the rates of target lesions and target vessel revascu-
larization. At present, four drug-eluting stents have been approved by the 
Food and Drug Administration, including the sirolimus-eluting stent (Cypher), 
paclitaxel-eluting stent (Taxus), zotarolimus-eluting stent (Endeavor) and 
everolimus-eluting stent (Xience V). These four drug-eluting stents are effec-
tive in reducing in-stent restenosis, and target vessel and lesion revascu-
larization in comparison with bare metal stents. However, the mortality and 
myocardial infarction rates were similar between bare metal stents and 
drug-eluting stents. Recently, late and very late stent thrombosis resulting 
in high rates of mortality and myocardial infarction have become impor-
tant issues. Discontinuation of dual antiplatelet therapy appeared to be 
the main etiology of late and very late stent thrombosis. Dual antiplatelet 
therapy for at least 12 months after deployment of drug-eluting stents is 
currently recommended by the ACC/AHA guidelines. [Tzu Chi Med J 2009;
21(1):18–27]
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1. Introduction
Since the first report of coronary angioplasty by 
Gruentzig et al in 1987, percutaneous coronary in-
tervention (PCI) has become the most common revas-
cularization procedure for occluded coronary artery 
disease [1]. The procedure provides a novel technique 
to expand the stenotic coronary lesion with a balloon 
catheter and thereby relieving the myocardial ischemia, 
which was only treated by coronary artery bypass 
graft surgery prior to the discovery of this technique. 
However, the rate of restenosis for patients undergo-
ing balloon angioplasty was as high as 30–50% within 
6 months of the PCI [2–4]. Coronary stents were devel-
oped to provide an intracoronary scaffolding device 
to reduce elastic recoil and remodeling, thus reducing 
the rate of restenosis. The stents did reduce the rate 
of restenosis. However, the rate of restenosis remained 
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unacceptably high (at about 10–30% of patients re-
ceiving PCI). This results in recurrent angina, impaired 
quality of life and the need for repeat PCI [4–6]. In 
2003, drug-eluting stents (DES) were approved by 
The Food and Drug Administration (FDA) and became 
commercially available to overcome the main defect 
of bare metal stents (BMS), that is, restenosis. The 
DES releases high local concentrations of immuno-
suppressive or antiproliferative drugs into the coro-
nary vessel wall at the site of stent deployment. The 
use of DES did reduce the rate of in-stent restenosis 
and the rate of reintervention [7–9]. Nevertheless, the 
answers to some issues, such as late thrombosis, 
duration of dual-antiplatelet therapy, and mortality 
benefits remained unclear.
2. Pathophysiology of restenosis
The pathophysiology of restenosis after PCI is not well 
understood. It is well accepted that restenosis is a 
maladaptive response to the trauma induced during 
angioplasty, which results in inflammation, thrombo-
sis, cellular proliferation and extracellular matrix pro-
duction. Inflammation and thrombosis occur at the 
time of vascular injury and are maximal within hours 
after the injury, resulting in acute closure after PCI. 
Cellular proliferation activity peaks at about 7 days 
post-injury. Finally, there is matrix formation from 
1 week onward [10]. The lumen loss after PCI can come 
in three distinct stages: early loss associated with 
elastic recoil, which usually occurs within 1 hour, late 
loss due to negative remodeling, and neointimal hyper-
plasia [11]. Negative remodeling results from collagen 
deposition in the matrix and adventitia thickening. 
Neointimal hyperplasia results from the pro liferation 
and migration of smooth muscle cells and extracellu-
lar matrix formation. Negative remodeling and neointi-
mal proliferation may occur within 1–6 months after 
angioplasty [11]. Artery remodeling plays an important 
role in restenosis after angioplasty without stenting, 
and implantation of BMS reduces the impact of elastic 
recoil and negative remodeling [2]. On the other hand, 
in-stent stenosis arises mainly from neointimal hyper-
plasia [2]. Damage to the vascular wall results in en-
dothelial damage and loss, endothelial dysfunction, 
vasoconstriction and inflammation. This starts the 
atherothrombotic cascade including platelet activa-
tion and adhesion [12]. This contributes to the release 
of mitogens including thromboxane A2, serotonin and 
platelet-derived growth factors. These factors then pro-
mote smooth muscle cell migration and proliferation, 
matrix formation, and cell proliferation [13].
Farb et al conducted a study involving 56 patients 
with 116 stents. Neointimal thickness, inflammatory 
cell density, and neointimal vascular channel density 
were significantly greater when the struts were in 
contact with the ruptured arterial media compared 
with the fibrous plaque or intact fibrous caps [14]. The 
data suggested that coronary stenting accompanied 
by medial damage and penetration of the stent into 
a lipid core induces increased arterial inflammation, 
which is associated with increased neointimal growth.
3. Evolution of DES
Because of the high restenosis rate of BMS, many ef-
forts have been made to reduce in-stent stenosis, in-
cluding brachytherapy (radiation therapy) and many 
systemic pharmacological approaches. Local delivery 
of drugs to inhibit neointimal proliferation has been 
tried for more than 20 years. Catheter-based drug de-
livery was unsuccessful in humans, partly owing to the 
short period of time the compounds remained within 
the vascular wall. The problem was resolved by incor-
porating drugs into a polymer matrix encapsulated 
over the stents to provide the platform from which 
controlled drug delivery was available during a pro-
grammed period of time. Many drugs were studied in 
DES, including paclitaxel and Limus family-related 
drugs, such as sirolimus, zotarolimus, biolimus A9 
and everolimus. Paclitaxel offers stabilization of mi-
crotubules and inhibits cell division in the G0/G1 
and G2/M phases, and hence inhibits neointimal hy-
perplasia [15]. The Limus family-related drugs were 
found to be effective in the inhibition of neointimal 
hyperplasia via binding to FKBP 12 binding protein, 
which subsequently binds to the mammalian target 
of rapamycin (mTOR) and blocks the cell cycle, pre-
dominantly of smooth muscle cells, from the G1 to S 
phase. These drugs were incorporated into the poly-
mer matrix on stents and were then delivered to coro-
nary arteries. The results of clinical trials have shown 
that DES reduced neointimal proliferation effectively 
and reduced the incidence of restenosis in compari-
son with BMS. Until now, four DES have been approved 
by the FDA. Cypher sirolimus-eluting stent (Cordis 
Corp., Miami, FL, USA) was the first, followed by Taxus 
paclitaxel-eluting stent (Boston Scientific Corp., Natick, 
MA, USA), Endeavor zotarolimus-eluting stent (Metronic 
Vascular, Santa Rosa, CA, USA) and the latest Xience V 
everolimus-eluting stent (Abbott Vascular, Santa Clara, 
CA, USA).
The sirolimus-eluting stent (SES) has a 5 μmol/L 
layer proximal to the metallic struts that is composed 
of a mixture of synthetic polymers blended with 
sirolimus and a diffusion barrier of drug-free polymer 
covering the sirolimus-containing layer, modulating 
the release of approximately 80% of the drug over 
approximately 30 days. The FDA-approved paclitaxel-
eluting stent (PES) (TAXUS) is coated with paclitaxel 
(1 μg/mm2 per unit area of the stent surface) in a slow- 
or moderate-release formulation of a proprietary 
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hydrocarbon-based elastomer [8]. The FDA-approved 
zotarolimus-eluting stent (ZES) (Endeavor) is coated 
with a phosphorylcholine polymer that is designed to 
target zotarolimus (10 μg/mm) delivery to the arterial 
wall [16]. Finally, the FDA-approved everolimus-eluting 
stent (EES) is coated with two polymers (an acrylic poly-
mer and a fluoro polymer) loaded with 100 μg of ever-
olimus per cm2 of stent surface area with the first 25% 
of the stent drug released on the first day after stent 
implantation and the remaining amount of the drug 
released over the following 4 months [17].
4. Major clinical trials of DES
4.1. Sirolimus-eluting stent (SES)
Sirolimus was the first of the Limus family of drugs to 
be used for endovascular prosthesis and was proven 
to be effective in the suppression of neointimal pro-
liferation via local or systemic delivery to the artery 
walls to inhibit mTOR activity [18–21]. A series of 
randomized controlled clinical trials were conducted 
to evaluate the efficacy and safety of SES in humans. 
The first landmark study was the RAVEL trial, which 
was a randomized controlled study to compare the 
in-stent restenosis rate and safety in native coronary 
arteries of angina patients who received SES or BMS 
[22]. A total of 238 patients with single, primary tar-
get lesions in native coronary arteries of 2.5–3.5 mm 
in diameter and less than 18 mm in length were ran-
domized to receive implantation of the SES (n = 120) 
or a BMS (n = 118). At 6 months, the mean in-stent late 
loss was significantly lower in the SES group than in 
the BMS group (−0.01 ± 0.33 mm vs. 0.80 ± 0.53 mm; 
p < 0.001). No cases of restenosis were observed in 
the SES group and 26.6% of cases in the BMS group 
had restenosis (p < 0.001). A 3-year follow-up of the 
RAVEL trial showed sustained clinical benefits in the 
cumulative event-free survival rates (for incidence of 
target vessel revascularization [TVR], target vessel fail-
ure [TVF], and major adverse cardiac events [MACE], 
including death, Q-wave or non-Q wave myocardial in-
farction [MI] and target lesion revascularization [TLR]) 
at 1, 2, and 3 years in SES group [23]. At almost the 
same time, the randomized, double-blind, SIRIUS study 
compared the safety and efficacy of SES and BMS in 
1058 patients (n = 533 and 525 in the SES and BMS 
group, respectively) with native coronary artery ste-
notic lesions in which more patients with diabetes, long 
lesions (mean, 14.4 mm) and small vessels (mean, 
2.8 mm) were included [24]. The primary end point 
was the failure of the target vessel (defined as death 
from cardiac causes, MI, revascularization, or repeat 
PCI) within 270 days of the procedure. A risk reduction 
of 58% was found in the SES group compared with the 
BMS group (4.1% vs. 16.6%; p < 0.001) which was 
mainly due to a reduction in the number of patients re-
quiring revascularization. The reduction in in-segment 
restenosis was significantly consistent among all sub-
group analyses, including age, gender, diabetes mel-
litus, left anterior descending artery involvement, 
vessel size or length and stent overlapping. The differ-
ences were maintained during the 2-year follow up 
and no differences in death, MI or stent thrombosis 
were seen between the two groups [25].
Two smaller studies of SES were performed in 
Europe (European SIRIUS [E-SIRIUS] trial) [26] and 
Canada (Canada SIRIUS [C-SIRIUS] trial) [27].
The E-SIRIUS trial enrolled 352 patients with sin-
gle de novo lesions of 15–32 mm in diameter. The 
minimum lumen diameter was significantly greater 
in the SES group than in the BMS group (2.22 mm vs. 
1.33 mm; p < 0.0001) after 8 months of follow up and 
fewer patients had MACE in the SES group, mainly 
due to a lower rate of TLR. The C-SIRIUS trial ran-
domized 100 patients with small target vessels to SES 
and BMS. At 9 months of follow up, late loss of lumen 
diameter (in-stent luminal diameter, 2.46 mm vs. 
1.49 mm; p < 0.001), angiographic in-lesion restenosis 
(2.3% vs. 52.3%; p < 0.001) and clinically driven TLR 
(4% vs. 18%; p = 0.05) were significantly lower in the 
SES group than in BMS group.
In a pooled analysis of the three SIRIUS trials with 
a total number of 1510 cases, the in-stent restenosis 
was reduced from 38.5% in the BMS group to 3.1% in 
the SES group and in-lesion restenosis was reduced 
from 39.8% in the BMS group to 7.5% in the SES 
group (p < 0.0001 for both comparisons) [28].
The Stenting Coronary Arteries in Non-Stress/
Benestent Disease (SCANDSTENT) trial included pa-
tients with more complicated lesions, including total 
occlusion (n = 115), bifurcations (n = 109), ostial lesions 
(n = 73), or angulations (n = 25) [29]. In-stent restenosis 
rates at the 6-month follow up favored the SES group 
(16.4% vs. 43.1%; p < 0.001). A continued benefit was 
observed for up to 3 years after stent implantation 
[30]. The rate of late adverse events was similar be-
tween the two groups and TLR was performed fewer 
times in the SES group than in the BMS group (4.9% 
vs. 33.8%; p < 0.001).
The results of the studies of SES consistently dem-
onstrated its effectiveness in reducing in-stent or in-
lesion restenosis, TLR and TVR in comparison with BMS. 
These effects have been demonstrated in patients 
with variable vessel sizes, lengths and complexities.
4.2. Paclitaxel-eluting stent (PES)
The PES, which is coated with paclitaxel, is currently 
available worldwide. There are other PES under inves-
tigation, such as the V-Flex Plus coronary stent (Cook 
Inc., Bloomington, IN, USA) and the 7-hexanoyltaxol 
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(QP2)-eluting polymer stent (QuaDS) (Quanam Medical 
Corp., Santa Clara, CA, USA). The first evidence that 
PES is effective in preventing in-stent restenosis was 
the results of the TAXUS 1 trial [31]. A total of 61 pa-
tients (31 received slow-release PES and 30 received 
BMS stents) with de novo or restenotic lesions (< 12 mm) 
and diameters of 3.0 mm or 3.5 mm were compared. 
Six-month angiographic restenosis rates were 0% for 
the PES group and 10% for the BMS group (p = not sig-
nificant). There were significant improvements in mini-
mal lumen diameter (2.6 mm vs. 2.2 mm; p < 0.01), 
diameter stenosis (13.6% vs. 11.8%; p < 0.01) and late 
lumen loss (0.36 mm vs. 0.78 mm; p < 0.01). No dif-
ference in the 30-day and 12-month MACE were found 
between the two groups. A similar study (TAXUS II), 
which included more patients (n = 536), was con-
ducted to compare the slow-release (SR; n = 131) and 
moderate-release (MR; n = 135) PES with BMS (n = 270) 
[32]. Significantly lower rates of angiographic in-stent 
restenosis were found in the SR group than in the 
BMS group (2.3% vs. 17.9%; p < 0.0001) and in the 
MR group than in the BMS group (4.7% vs. 20.2%; 
p = 0.0002) after 6 months of follow-up. The incidence 
of MACE (a composite of cardiac death, MI and repeat 
revascularization) at 12 months was significantly lower 
(p = 0.0192) in the SR (10.9%) and MR (9.9%) groups 
than in the BMS group (22.0% and 21.4%, respec-
tively), which was predominantly due to a significant 
reduction in repeat TLR in the PES-treated patients.
The TAXUS IV trial was designed to evaluate single 
de novo coronary lesions of 10–28 mm in length and 
2.5–3.75 mm in diameter covered using a single study 
stent [33]. A total of 662 patients were assigned to 
the SR PES group and 652 patients were assigned to 
the BMS group. At 12 months of follow up, in com-
parison with BMS, PES reduced TLR by 73% (4.4% 
vs. 15.1%; p < 0.0001), TVR by 62% (7.1% vs. 17.1%; 
p < 0.0001), the TVF rate by 52% (10.0% vs. 19.4%; 
p < 0.0001), and composite major adverse cardiac 
events by 49% (10.8% vs. 20.0%; p < 0.0001). The 
rates of subacute thrombosis were similar between 
the two groups. There were fewer episodes of MI in 
the PES group than in the BMS group (0% vs. 1.1%; 
p = 0.007), TVR (2.4% vs. 6.3%; p = 0.0009) and MACE 
(2.4% vs. 6.3%; p = 0.0009) between 9 and 12 months 
after implantation.
The later TAXUS V and TAXUS VI trials were de-
signed to evaluate the safety and efficacy of the SR- 
and MR-PES in more complex lesions [34,35]. About 
half of the lesions in the TAXUS V study (n = 1156) 
were complex, previously unstudied, long lesions 
(10–46 mm in length), requiring stent diameters of 
2.25 mm or 4.0 mm, and/or multiple stents. At the 
9-month angiographic follow-up examinations, the rates 
of TVR and in-stent restenosis were lower in the PES 
group than in the BMS group (12.1% vs. 17.3%; 
p < 0.02 and 13.7% vs. 31.9%; p < 0.001, respectively). 
The TAXUS VI trial enrolled 446 high-risk patients, 
including those with lesion lengths > 20 mm, vessel 
diameters < 2.5 mm, overlapping stents, ACC/AHA 
type C lesions, and those being treated for diabetes. 
At 9 months, a 53% risk reduction in TVR (9.1% vs. 
19.4%; p = 0.0027) and 64% risk reduction in TLR 
(6.8% vs. 18.9%; p = 0.0001) were found in the PES 
group compared with the BMS group.
The results of these studies demonstrated the 
beneficial effects of PES in reducing in-stent resteno-
sis. TVR and TLR were consistent in variable lesion 
lengths, lesion sizes, stent diameters, lesion complexity 
and even in diabetic patients in comparison with the 
effects of BMS.
4.3. Zotarolimus-eluting stent (ZES)
Zotarolimus, a Limus family related drug, has anti-
proliferative and anti-inflammatory effects. Incorpo-
ration of the tetrazole ring within the zotarolimus 
chemical structure increases lipophilicity and facili-
tates its ability to cross the membranes of smooth 
muscle cell to initiate the blockage of normal cell-
cycle division.
The ENDEAVOR I trial was a first-in-human, non-
randomized, prospective, single-arm study (n = 100), 
which was designed as a preliminary feasibility study 
to evaluate the safety and efficacy of the ZES in the 
treatment of single, de novo, native coronary lesions 
of less than 15 mm in length and 3.0–3.5 mm in diam-
eter [36]. The binary angiographic restenosis rates (de-
fined as > 50% diameter stenosis) at 4 and 12 months 
were 2.1% and 5.4%, respectively. The cumulative in-
cidence of MACE (defined as death, MI, emergent car-
diac surgery or repeat revascularization of the index 
lesion) was 1% at 30 days and 2% at 4 and 12 months. 
The results demonstrated that the ZES is reliable and 
safe for treating obstructive coronary artery disease. 
The incidence of MACE was 3% at 2 years, 6.1% at 
3 years and 7.2% at 4 years. From 2–4 years, there 
was only one additional reported case of TLR [36]. 
Only one case of stent thrombosis occurred at 10 days 
after the index procedure, but no cases occurred 
thereafter.
The ENDEAVOR II trial compared ZES (n = 598) with 
BMS (n = 599) in de novo native coronary lesions with 
diameters of 2.25–3.5 mm and lengths of 14–27 mm 
[37]. At 9 months, TVR had reduced from 15.1% to 
7.9%, TLR had reduced from 11.8% to 4.6% and the 
rates of MACE had reduced from 14.4% to 7.3% 
(p = 0.0001 for all). Stent thrombosis was similar in 
the ZES and BMS groups (0.5% vs. 1.2%; p = NS). In the 
531 patients who underwent angiographic follow-up, 
late loss was reduced from 1.03 to 0.61 (p < 0.001) 
in the stent and from 0.72 to 0.36 (p < 0.001) in the 
segment. The rate of in-segment restenosis had 
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reduced from 35.0% to 13.2% with ZES (p < 0.0001). 
Differences in clinical outcomes were maintained at 
12 and 24 months (p < 0.0001).
The results of the two studies demonstrated the 
effects of ZES on restenosis and TLR/TLR. Other stud-
ies of ZES are still ongoing.
To conclude, these three DES (SES, PES and ZES) 
consistently demonstrated the clinical benefits of 
DES in reducing restenosis in addition to preventing 
TVR and TLR. Thus the short-term safety profile is 
acceptable.
4.4. Everolimus-eluting stent (EES)
Everolimus is another Limus family-related drug and 
is a powerful anti-proliferative agent that forms a 
complex with the cytoplasmic protein FKBP12. It can 
inhibit growth factor-stimulated phosphorylation of 
p70 S6 kinase and 4E-BP1. Moreover, it can bind to 
and interfere with the function of FKBP12-rapamycin 
associated protein (FRAP), which is a key regulatory 
protein of cell metabolism, growth and proliferation. 
By this process, everolimus can cause cell-cycle arrest 
during the late G1 stage.
The main clinical data for EES is the SPIRIT clinical 
trial program. The SPIRIT first-in-man trial was a pro-
spective single-blind, randomized, controlled multi-
center study [17]. A total of 60 patients with single 
de novo lesions of 3.0 mm in diameter and less than 
12 mm in length were randomly assigned to receive 
EES (28 patients) or BMS (32 patients). At 6 months, 
angiographic results showed significantly less in-stent 
late loss in the EES group than in the BMS group 
(0.10 mm vs. 0.87 mm; p < 0.001) and in-segment late 
loss (0.07 mm vs. 0.61 mm; p < 0.001). At 1 year, TLR 
was 7.7% vs. 21.4% (p < 0.001) and MACE was equiv-
alent (15.4% vs. 21.4%; p = not significant).
5. Head to head comparison of DES
The first randomized, controlled trial of a head-to-head 
comparison of SES and PES was the TAXi trial [38]. 
At 7 months of follow up, there were no significant 
differences between the PES group (n = 100) and the 
SES group (n = 102) in MACE (4% vs. 6%; p = 0.8) or 
TVR (1% vs. 3%). Later, three large-scale studies were 
conducted to assess the differences between these 
two DES. The first trial compared MACE (death, MI, 
and ischemia-driven revascularization of the target 
lesion) between the SES (n = 503) and PES groups 
(n = 509) at 9 months [39]. The SES group had lower 
MACE at 9 months compared with that in the PES 
group (6.2% vs. 10.8%; p = 0.009). The differences 
were driven mainly by a lower rate of ischemia-driven 
target-lesion revascularization in the SES group. 
Follow-up angiography was performed in 53.4% of 
cases and lower rates of angiographic restenosis were 
found in the SES group than in the PES group (6.6% 
vs. 11.7%; p = 0.02). The second study was the 
REALITY trial, which was a prospective, randomized, 
multicenter study that assessed SES and PES in 1386 
patients with moderate complex lesions. No differ-
ences in the primary end points (in-lesion binary res-
tenosis) between the SES and PES groups (9.6% vs. 
11.1%; p = 0.31) were found. Rates of MACE (TLR, 
TVR, and composite end point of cardiac death, 
Q-wave or non Q-wave MI, coronary artery bypass 
graft surgery, or repeat TLR) at 1 year were similar 
between the SES and PES groups (10.7% vs. 11.4%; 
p = 0.73). In-stent late loss (0.09 mm vs. 0.31 mm; 
p < 0.001) and in-stent diameter stenosis (23.1% vs. 
26.7%; p < 0.001) were lower in the SES compared 
with the PES groups [40].
The third study was the SORT OUT II randomized 
trial, which compared PES (n = 1033) with SES (n = 
1065). All patients were observed from randomiza-
tion to death, emigration, or for up to 18 months after 
randomization [41]. There were no differences in the 
primary end points (MACE, including cardiac death, 
acute MI, TLR, or TVR: 9.3% vs. 11.2%; p = 0.16) or 
stent thrombosis (2.5% vs. 2.9%; p = 0.60) between 
the SES and PES groups. Two meta-analyses of rand-
omized trials demonstrated that the SES group had 
a significantly lower risk of restenosis and TVR com-
pared with the PES group. Rates of death or MI were 
similar [42,43].
The two DES have also been compared in differ-
ent patient groups or vessel situations. The ISAR-
DIABETES study assessed the use of SES and PES in 
diabetic patients [44]. In a total of 250 patients with 
diabetes and coronary artery disease, 125 were ran-
domly assigned to receive PES and 125 to receive 
SES. Angiographic follow up at 6.5 months (mean 
duration) demonstrated a 0.24 mm increase in in-
segment late lumen loss (p = 0.002) in the PES group. 
In-segment restenosis was lower in the SES group 
than in the PES group (6.9% vs. 16.5%; p = 0.03) and 
no differences were noted in the TLR (6.4% vs. 
12.0%; p = 0.13). The Long-DES II study assessed the 
use of long SES and PES (stent length > 32 mm) 
in 500 patients with long coronary artery lesions 
(> 25 mm) [45]. The follow-up angiography at 6 months 
demonstrated a lower rate of angiographic in-segment 
binary restenosis (3.3% vs. 14.6%; p < 0.001) and 
in-stent late loss of lumen diameter (0.09 mm vs. 
0.45 mm; p < 0.001) in the SES than in the PES group. 
At 9 months, the TLR was lower in the SES group 
than in the PES group (2.4% vs. 7.2%; p = 0.012). 
There were no differences in the incidence of death 
(0.8% vs. 0%; p = 0.049) or MI (8.8% vs. 10.8%; 
p = 0.452) between the PES and SES groups. The 
ISAR-SMART 3 study also demonstrated that PES was 
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associated with a greater late luminal loss and was 
less effective in reducing restenosis in small coro-
nary vessels than SES [46].
Until now, only one study (ENDEAVOR III) has com-
pared the safety, clinical efficacy and angiographic 
outcomes between ZES and SES [47]. A total of 436 
patients with de novo native coronary lesions with 
diameters 2.5–3.5 mm and lesion lengths 14–27 mm 
were randomized to the ZES (n = 323) and SES (n = 113) 
groups. The primary end point, 8-month angiographic 
in-segment late lumen loss, was significantly higher 
in the ZES group than in the SES group (0.34 mm vs. 
0.13 mm; p < 0.001). Inhospital MACE was lower in 
patients treated with ZES (0.6% vs. 3.5%; p = 0.04). 
Higher in-segment binary angiographic restenosis and 
TLR were found in the ZES group at 9 months (11.7% 
vs. 4.3%; p = 0.04 and 9.8% vs. 3.5%; p = 0.04, respec-
tively). No significant differences in clinically driven 
TLR or TVF were found [47]. The ENDEAVOR IV trial 
was designed to compare the primary noninferiority 
endpoints of TVF among 1548 patients randomized 
(1:1) to treatment with ZES or PES. The study is still 
going on [48].
The SPIRIT II and III trials compared EES and PES. 
In the SPIRIT II trial, a total of 300 patients with de 
novo native coronary artery lesions with diameters 
of 2.5–3.75 mm and lengths less than 28 mm were 
randomized to the EES group or the PES group at a 
3:1 ratio [49]. At 6 months of follow up, in-stent late 
loss was 0.12 mm for the EES group and 0.37 mm for 
the PES group (p < 0.0001). Similar results were 
found for in-stent binary restenosis (1.3% vs. 3.5%; 
p = 0.194), TLR (2.7% vs. 6.5%; p = 0.157), cardiac 
death (0% vs. 1.3%; p = 0.257), MI (0.9% vs. 2.6%; 
p = 0.272) and stent thrombosis (0.5% vs. 1.3%; 
p = 0.448). SPIRIT III was a prospective, randomized, 
single-blind, multicenter, controlled trial that enrolled 
1002 patients with de novo coronary artery lesions 
with diameters of 2.5–3.75 mm and lengths less than 
28 mm [50]. Patients were randomized 2:1 to receive 
EES or PES. The angiographic follow up at 8 months 
showed less in-segment late loss in the EES group 
than in the PES group (0.14 mm vs. 0.28 mm; p < 0.004). 
EES was non-inferior to PES for TVF at 9 months 
(7.2% vs. 9%; p < 0.001). A significant reduction in 
MACE was found in the EES group than in the PES 
group at 9 months (4.6% vs. 8.1%; p = 0.03) and at 
12 months (6.0% vs. 10.3%; p = 0.02), due to fewer 
episodes of MI and TLR.
In brief, SES does not seem to be inferior to PES 
in terms of in-stent restenosis rates. In addition, the 
rates of TVR and TLR, as well as mortality and MI, 
were similar. In comparison with ZES, patients receiv-
ing SES also showed better clinical outcomes in terms 
of restenosis and TVR/TLR with borderline higher in-
hospital MACE. Patients who received EES did better 
in late loss than those who received PES.
6. Long-term outcomes and late/very 
late thrombosis
As shown in previous studies, in comparison with 
BMS, DES reduced in-stent restenosis, TVR and TLR 
effectively. However, long-term safety is another con-
cern. The REAL multicenter registry trial assessed 
the 2-year safety and efficacy of DES [51]. The re-
searchers assessed a total of 10,629 patients who 
underwent elective PCI with either DES (n = 3064) or 
BMS (n = 7565). The 2-year cumulative incidence of 
death was 6.8% in the DES group and 7.4% in the 
BMS group (p = 0.35) and the rates of MI were 5.3% 
in the DES group and 5.8% in the BMS group 
(p = 0.46). MACE was lower in the DES group than in 
the BMS group (16.9% vs. 21.8%; p < 0.0001), which 
was mainly due to lower rates of TVR in the DES 
group (9.1% vs. 12.9%; p < 0.00001). No significant 
differences were found but there was a trend for 
higher rates of angiographic stent thrombosis in the 
DES group (1.0% vs. 0.6%; p = 0.09). The data dem-
onstrated similar safety profiles between DES and 
BMS. A 4-year follow up also demonstrated an equiv-
alent safety profile between SES and BMS [52]. In 
this pooled analysis of 1748 patients, both the SES 
and BMS groups had similar survival rates (93.3% 
vs. 94.6%; p = 0.28), MI (6.4% vs. 6.2%; p = 0.86) 
and stent thrombosis, as defined by the Academic 
Research Consortium (ARC) [53] (3.6% vs. 3.3%; 
p = 0.8). In a large outcome study, researchers as-
sessed 6033 patients treated with DES and 13,738 
patients with BMS. At a 3-year follow up examina-
tion, a significantly higher event rate after 6 months 
was found in the DES group with 12.7 more events 
per 1000 patients per year (adjusted relative risk, 
1.20; 95% confidence interval, 1.05–1.37). At 3 years 
of follow up, the mortality rate was significantly higher 
in the DES group (adjusted relative risk, 1.18; 95% 
confidence interval, 1.04–1.35) and from 6 months 
to 3 years, the adjusted relative risk for death in this 
group was 1.32 (95% confidence interval, 1.11–1.57). 
The results of this study showed that DES was asso-
ciated with an increased rate of death, as compared 
with BMS, and this trend appeared after 6 months 
when the risk of death was 0.5% higher and a 
composite of death or MI was 0.5–1.0% higher per 
year [54].
Even with the safety profile reports and fewer 
revascularizations after using DES, the use of DES 
has raised some concerns about late and very late 
stent thrombosis. The classification of stent throm-
bosis was provided by the ARC, which defined the 
occurrence of late stent thrombosis as events occur-
ring between 1 month and 1 year after PCI and very 
late stent thrombosis as events occurring more than 
1 year after PCI [53]. Stent thrombosis resulted in 
a high rate of death (31% vs. 3%; p < 0.001) [55]. 
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Stone et al also demonstrated a 91.1% of death or 
MI within 7 days of stent thrombosis [56].
Although some studies showed that the rates of 
stent thrombosis were similar with DES and BMS 
[51,52,57], many studies showed higher rates of late 
and very late stent thrombosis in patients who under-
went DES. In a meta-analysis study of SES, PES and 
BMS with 4 years of follow up, more very late throm-
bosis was observed in both the SES and PES groups 
than in the BMS group (0.6% vs. 0.0%; p = 0.025 and 
0.7% vs. 0.2%; p = 0.028, respectively) [58]. Another 
3-year follow-up study also demonstrated higher stent 
thrombosis in the SES and PES groups than in the BMS 
group (2.7%, 2.9% and 1.6%, respectively). Cumulative 
mortality rates were similar in these three groups [59]. 
According to data from a large two-institutional cohort 
study, late thrombosis was encountered steadily with 
no evidence of diminution at up to 3 years of follow 
up. Late thrombosis occurred at a steady rate of 
0.6% per year [60]. Real world data also demonstrated 
an average stent thrombosis rate of 1.3% during a 
9-month follow-up period [61].
7. Mechanism and predictors of late 
stent thrombosis
Many studies have been designed to evaluate the 
mechanism of late stent thrombosis. In an animal 
study, SES, PES, and BMS (BxVelocity or Express) were 
examined using the arterial reaction in rabbits [62]. 
Stented arteries were harvested at 28 and 90 days 
after insertion for histology. The results showed that 
the BxVelocity stent (BMS) group had significantly 
higher endothelialization than the SES group (96% 
vs. 75%; p = 0.04) and the Express stent (BMS) showed 
a trend towards higher endothelialization than the 
PES (80% vs. 67%; p = not significant) at day 28. The 
study also showed higher levels of inflammation pa-
rameters, such as fibrin scores, struts with fibrin, giant 
cells per strut and luminal heterophils and eosinophils 
in the DES overlap site than in the BMS. In comparison 
with BMS, DES delayed arterial healing and promoted 
inflammation. Hofma et al also compared the endothe-
lial function between the SES (n = 7) and the BMS (n = 5) 
[63]. Endothelium-dependent vasomotion of a coro-
nary segment of 15 mm in length at 2 mm distal to the 
stent was assessed with intracoronary infusion of ace-
tylcholine. Significant vasoconstriction was seen in 
the SES group (median 32% diameter reduction from 
baseline) but not in the BMS group (median 2% re-
duction) after acetylcholine infusion (p = 0.03). There 
were no differences in endothelium-independent va-
sodilatation to nitrate between the two groups. The 
results illustrated that SES implantation may have 
adverse effects on local endothelium-dependent va-
somotor responses compared with BMS implantation 
at 6 months. This may partially explain the phenome-
non of late stent thrombosis. Kotani et al also demon-
strated that SES had incomplete neointimal coverage 
at 3–6 months after implantation, according to angio-
scopic findings [64]. All these phenomena, including 
incomplete neointimal coverage, endothelial dysfunc-
tion and less endothelialization with higher rates of 
inflammation, are associated with subclinical throm-
bus formation. Autopsy data from 23 patients with 
DES (SES and PES) and 25 matched autopsies of BMS 
implantation also showed greater delays in healing in 
those who received DES, characterized by persistent 
fibrin deposition and poorer endothelialization [65].
Many factors account for the higher rates of late 
stent thrombosis in those receiving DES. Discontinua-
tion of thienopyridine therapy was thought to be a 
major determinant of stent thrombosis. In one study 
[66], 3021 patients with 5389 lesions who received 
DES were studied and the incidence of stent thrombo-
sis during an 18-month follow-up period was analyzed. 
The rate of stent thrombosis was 1.9% and the strong-
est predictor for stent thrombosis within 6 months of 
stenting was discontinuation of thienopyridine therapy 
(hazard ratio, 13.74; 95% confidence interval, 4.04–
46.68; p < 0.001). Nevertheless, insufficient informa-
tion is available to determine whether there is benefit 
in continuing thienopyridine beyond 6 months. Other 
risk factors predisposing to late and very late stent 
thrombosis included renal failure, treatment for in-
stent restenosis and bifurcation lesions, diabetes, 
acute coronary syndrome at presentation, primary 
stenting in acute MI, total stent length and low ejec-
tion fraction [55,60,61,67].
8. Optimal duration of dual antiplatelet 
therapy
Late and very late stent thromboses almost always 
result in serious adverse events, including MI and 
death, and may outweigh the benefits of DES in reduc-
ing restenosis and TLR/TVR. Many studies demon-
strated that the most predictable factor for late and 
very late thrombosis in DES implantation was discon-
tinuation of dual antiplatelet therapy [55,61,66,67]. 
The BASKET-LATE trial evaluated the rates of cardiac 
death and MI for 18 months after clopidogrel discon-
tinuation in DES and BMS patients [68]. The rates of 
cardiac death and MI over 18 months were not differ-
ent between DES and BMS groups but the proportion 
of events was significantly higher in DES than in BMS 
(4.9% vs. 1.3%) after the discontinuation of clopidog-
rel (between months 7 and 18). In the PREMIER trial, 
the mortality and cardiac hospitalization rates during 
an 11-month period after stopping thienopyridine 
therapy were evaluated in people treated with DES 
[69]. Among 500 DES-treated MI patients, the patients 
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who stopped thienopyridine therapy by day 30 were 
more likely to die (7.5% vs. 0.7%; p < 0.0001) or to 
be rehospitalized (23% vs. 14%; p = 0.08) during the 
11 months following the discontinuation. These two 
studies showed the importance of prolonged dual 
antiplatelet therapy in DES patients.
The optimal duration of dual antiplatelet therapy 
(aspirin and thienopyridine) is still a matter of ongo-
ing debate. The most recent ACC/AHA guidelines 
published in 2008 recommended that 162–325 mg 
of aspirin should be given for at least 3 months after 
SES implantation and 6 months after PES implanta-
tion, after which daily long-term low-dose aspirin 
(75–162 mg) should be continued. In addition, a daily 
dosage of 75 mg clopidogrel should be given for at 
least 12 months in patients receiving DES [70]. Ac-
cording to this recommendation, at least 12 months 
of dual antiplatelet therapy is warranted for DES im-
plantation to prevent unfavorable clinical outcomes. 
DES can thus be limited to those suitable for long-
term (at least 12 months) dual antiplatelet therapy. 
For those who are scheduled for surgery requiring 
premature discontinuation of dual antiplatelet ther-
apy, those with poor drug compliance, those at high 
risk of bleeding and those who are intolerant of dual 
antiplatelet therapy, DES implantation should be 
avoided if possible.
9. Conclusion
At the present time, PCI is the most important strat-
egy in the treatment of coronary artery diseases. 
BMS reduced the rate of restenosis and acute closure 
in comparison to balloon angioplasty. The rate of res-
tenosis of patients receiving BMS remains high. DES 
effectively reduced the rate of in-stent restenosis, 
TVR and TLR without additional benefits in mortality 
rates and MI compared with BMS. Observational data 
have raised many concerns about late and very late 
stent thrombosis in those receiving DES. Discontinu-
ation of dual-antiplatelet therapy was shown to be the 
main etiology. The optimal duration of dual antiplate-
let therapy remains to be debated. Dual antiplatelet 
therapy for at least 12 months after DES implanta-
tion is recommended by the ACC/AHA guidelines. 
The development of newer generations of DES to fur-
ther reduce in-stent restenosis and stent thrombosis 
is expected.
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